Browsing Tag: Recurrent Nasopharyngeal Carcinoma

Takeaways:  BeOne Medicines has cleared the key reimbursement hurdles in Canada for Tevimbra + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metastatic...